FDA has granted regular approval to dasatinib (Sprycel) for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
